US CDC Advisory Committee recommends Johnson & Johnson vaccination… Secure 3 vaccines

After FDA approval for emergency use, only the signature of the CDC director remains… Distribution of 4 million times per week

photo-group">

Johnson & Johnson vaccine

[로이터=연합뉴스]

(Washington = Yonhap News) Correspondent Ryu Ji-bok = The Vaccination Advisory Committee (ACIP), an advisory body of the CDC A decision was made to recommend vaccination for the vaccine.

As a follow-up to the Food and Drug Administration’s (FDA) approval of the urgent use of the J&J vaccine on the 27th, the day before, the administrative procedures required for the use of the vaccine are now signed only to accept the recommendations of the CDC director.

According to the Washington Post (WP) and others, ACIP held a meeting that day and unanimously decided on the recommendation in a vote recommending J&J vaccination to those over 18 years old.

The advisory committee strongly supported the effectiveness of the vaccine in protecting against hospitalization and death, the WP said.

With this, the United States became a country that secured the third vaccine available in the field after the pharmaceutical company Modena and Pfizer-Bioentech vaccine.

In particular, the J&J vaccine, unlike Pfizer and Modena vaccines that require two doses, ends with a single dose and does not have to be stored frozen, saving time and energy from investing in restrictions on distribution and storage of vaccines, and inoculation reservation and schedule management. The advantage is to give.

For example, health officials explained that the vaccine will be available to rural and remote medical facilities without refrigeration facilities.

Delivery of the J&J vaccine will begin soon, and 4 million doses will be distributed to hospitals and pharmacies during the week.

In addition, 20 million doses will be supplied to the United States by the end of March and 100 million doses in the first half.

As a result of Johnson & Johnson’s Phase 3 clinical trial in the United States and South Africa with 44,000 people, 72% in the US and 64% in South Africa were shown.

It is lower than that of Pfizer (95%) and Modena (94.1%), but it should be taken into account that the clinical trials of these two companies were conducted prior to the spread of the mutant virus.

The preventive effect of the J&J vaccine against severe Corona 19 was 86% in the United States and 82% in South Africa, respectively, and no one died from Corona 19 after getting the vaccine.

[email protected]

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.